Ampreloxetine
0179
Phase 1 small_molecule completed
Quick answer
Ampreloxetine for Symptomatic Neurogenic Orthostatic Hypertension is a Phase 1 program (small_molecule) at Theravance Biopharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Theravance Biopharma
- Indication
- Symptomatic Neurogenic Orthostatic Hypertension
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed